| 1.15 -0.11 (-8.73%) | 04-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.47 |
1-year : | 1.71 |
| Resists | First : | 1.25 |
Second : | 1.47 |
| Pivot price | 1.17  |
|||
| Supports | First : | 0.92 |
Second : | 0.76 |
| MAs | MA(5) : | 1.23 |
MA(20) : | 1.14 |
| MA(100) : | 1.06 |
MA(250) : | 1.41 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.1 |
D(3) : | 54.9 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 2.56 | Low : | 0.88 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TCRX ] has closed above bottom band by 44.1%. Bollinger Bands are 89.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.26 - 1.26 | 1.26 - 1.27 |
| Low: | 1.12 - 1.12 | 1.12 - 1.13 |
| Close: | 1.14 - 1.15 | 1.15 - 1.16 |
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Mon, 27 Apr 2026
TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
Mon, 27 Apr 2026
TScan brings post-transplant cancer relapse research to Boston meeting - Stock Titan
Tue, 21 Apr 2026
TCRX Financials: Income Statement, Balance Sheet & Cash Flow | Tscan Therapeutics, Inc. - Stock Titan
Wed, 15 Apr 2026
TCRX: TCR T cell therapy shows >50% relapse reduction in AML/MDS, pivotal trial starts mid-2024 - TradingView
Thu, 02 Apr 2026
TScan Therapeutics announces resignation of vice president of finance - Investing.com
Thu, 02 Apr 2026
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 65.7 (%) |
| Shares Short | 1,890 (K) |
| Shares Short P.Month | 1,930 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.16 |
| Profit Margin | 0 % |
| Operating Margin | -851.5 % |
| Return on Assets (ttm) | -27.9 % |
| Return on Equity (ttm) | -71.3 % |
| Qtrly Rev. Growth | 286 % |
| Gross Profit (p.s.) | -1.95 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -2.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -135 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -1.15 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 5.86 |
| Price to Cash Flow | -0.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|